UV Applied: Consolidates Supply Chain, Engineering, New Product Development, Logistics and Manufacturing – Form 8-K

0

Applied UV consolidates supply chain, engineering, new product development, logistics and manufacturing

Consolidation review continues to unlock new synergies in three recent acquisitions

Max Munn, Founder, President and Director appointed Interim CEO

MOUNT VERNON, NY / ACCESSWIRE / December 27, 2021 /Applied UV, Inc. (NASDAQ: AUVI) (“Applied UV” or the “Company”), a pathogen removal technology company that applies the power of short-range ultraviolet light (“UVC”) to surfaces and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly and automatically, announced that an initial review of operations, supply chain, manufacturing, New product development, logistics and distribution processes of recently acquired acquisitions (Akida Holdings, Kes Science and Technology and Scientific Air Management) is completed. In an effort to maximize synergies between them, the company chose to relocate Applied UV’s operations from Denver to Atlanta, Georgia, using Kes’ science and technology facilities. The company also consolidated the operations of its recently acquired Scientific Air Management company at the Kes Science Facility in Atlanta, Georgia.

In addition, the Applied UV Board of Directors also unanimously approved and promoted John J. Hayman, III., CEO and President of our 100% owned and recently acquired KES Science and Technology company by the Vice -President of Operations as Interim Chief Operating Officer of Applied UV. Officer. Mr. Hayman was President and CEO of Kes Science for 18 years, leading the company’s growth, R&D and new product development. Prior to Kes, Mr. Hayman was an accountant where he obtained his COA certification and completed his tenure as a certified public account with KMPG. M. Hayman replaces James L. Doyle III.

Finally, the Company was notified on December 21st, 2021 that James Alecxih, CEO of Applied UV and director of the board of directors, has resigned. Mr. Alecxih’s resignation was for personal reasons and not the result of disagreement with the Company on any matter relating to the operations, policies or practices of the Company. Max Munn, Founder, Chairman of Applied UV as well as a Director on the Board of Directors and principal shareholder, has been appointed Interim Chief Executive Officer.

Max Munn said, “In addition to consolidating facilities, with the goal of facilitating the reduction of duplicate costs and maximizing synergies between all platforms, we also plan to consolidate all of our marketing efforts which, We believe will further enhance the opportunity to grow and grow revenue through cross-selling and marketing of all of the acquired company’s different product lines and verticals served through our extensive existing global distribution channels. ”

About applied UVs

Applied UV is focused on the development and acquisition of infection control technologies in the healthcare, hospitality, commerce and municipal markets. The Company has two wholly owned subsidiaries – SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s Connected Platform for Data-Driven Disinfection ™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, completely and automatically, meeting the challenge of nosocomial infections (“HAI”) . Intended for use in high customer turnover facilities such as hospitals, hotels, commercial facilities and other public spaces, the company’s Lumicide ™ platform uses UVC LEDs in several patented designs for the control of infections in and around high traffic areas, including sinks and toilets, killing bacteria, viruses and other pathogens residing on hard surfaces near appliances. The company’s patented drain disinfection device, Lumicide Drain, is the only product on the market that tackles this critical, pathogen-intensive location. SteriLumen’s Airocide® air purification devices are research-backed, clinically proven and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II medical device, uses proprietary photo-catalytic bioconversion (PCO) technology that draws air into a reaction chamber that converts harmful molds, microorganisms, agents Hazardous airborne pathogens, destructive VOCs, allergens, odors and biological gases into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, chain grocery stores, winemaking facilities, commercial real estate, schools, dental offices, post-harvest services, grocery stores, cannabis facilities and houses.

For more information about Applied UV, Inc. and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; https: //www.airocide.comhttps: //kesscience.com; https://scientificairmanagement.com and https://munnworks.com/.

Forward-looking statements

The information contained in this document may contain “forward-looking statements”. Forward-looking statements reflect the current view of future events. When used in this press release, the words “anticipate”, “believe”, “estimate”, “expect”, “the future”, “intend”, “plan” or the negative of these terms and similar expressions, when they relate to us or our management, identify forward-looking statements. These statements include, but are not limited to, statements in this press release regarding the opinion of the management of Applied UV with respect to its business strategy, future results of operations and prospects for liquidity and capital resources. . Forward-looking statements are based on the Company’s current expectations and assumptions regarding its business, economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The actual results of the Company may differ materially from those contemplated by forward-looking statements. They do not constitute statements of historical fact or guarantees of future performance. We therefore advise against relying on any of these forward-looking statements. Factors or events that could cause the actual results of the Company to differ may arise from time to time and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, activity levels, performance or achievements. Except as required by applicable law, including United States securities laws, the Company does not intend to update any forward-looking statements to conform them to actual results.

For more information about the company:
Applied UV inc.
Max Munn
Interim CEO of Applied UV
[email protected]

Contact:
Applied UV Investor Relations
Kevin McGrath
TraDigital IR
+ 1-646-418-7002
[email protected]

Share.

Comments are closed.